Anthropic 收购一人 AI 生物科技公司 Mithril Medicine
Anthropic bought a one-person, AI-powered biotech: is this drug discovery’s future?
Anthropic 收购了仅有一名全职员工的生物科技公司 Mithril Medicine,该公司利用 AI 技术开发了针对罕见肌肉萎缩症的抗体药物。这引发了关于未来药物发现是否将更多依赖 AI 的讨论。Mithril Medicine 通过聘请顾问和外包实验,利用 AI 分析数据,简化了研发流程。
- NEWS
- 11 November 2026
A promising biotechnology company developed a new approach that might treat a rare disease — but its sole employee didn’t do all the work.
By
-
Heidi Ledford
-
Heidi Ledford reports for Nature from Seattle, Washington.
-

Minimalist biotechnology companies that have just a handful of employees — or even as few as one — are becoming more feasible with the rise of artificial-intelligence tools.Credit: Getty
How many scientists does it take to discover a drug?
The question came to the fore after news that a biotechnology company armed with an artificial-intelligence assistant, two promising drug leads and just one full-time human employee had been acquired by San Francisco-based Anthropic as part of the AI giant’s expansion into biomedical science.
AI agents run this automated biology lab that sequences DNA and more
In truth, it took many human scientists to develop the molecules that are the mini-company’s star products: two antibodies that are still in the early stages of development and were designed to treat a rare form of muscular dystrophy. The company, Mithril Medicine in Cambridge, Massachusetts, also hired part-time consultants to advise on the project, and paid at least five contract research organizations to conduct experiments. Many more researchers will be needed to carry the drug further, especially if it eventually enters clinical trials. “It takes a village to develop a drug,” says Jeb Keiper, a partner at Third Rock Ventures, a venture-capital firm in Boston, Massachusetts.
But the news sparked a wave of discussions about whether the one-person biotech is the drug-discovery business model of the future. “We will see more and more of these small teams that are enabled by AI,” says James Zou, a computer scientist who works on biomedical applications of AI at Stanford University in California. “They will be very powerful for identifying good opportunities and moving quickly.”
Pint-sized powerhouses
Itsy-bitsy biotechs are not a new concept. Entrepreneur Matt Davidson started his first biotech company in 2013, nearly a decade before ChatGPT’s public debut. Davidson kept the roster trim for years, with only two full-time employees until the drug he was developing was ready to enter late-stage clinical testing. The company never had a physical laboratory, Davidson says. All the lab work was contracted out.
His current company, Azora Therapeutics in Los Angeles, California, has a whopping five employees. He uses AI more for summarizing reports than for scientific discovery and says that AI tools have made tiny biotechs more efficient. “We use consultants a little bit less than we used to,” he says.
Anthropic’s AI biolab finds ‘CRISPR-like’ DNA in viruses. What’s next?
Mithril Medicine leaned more heavily on AI than Azora does, and tasked Anthropic’s AI assistant Claude with helping to analyse data and suggesting next steps, as well as taming the piles of emails and paperwork that come from working with multiple contract research organizations. “What began as an exercise in staying lean evolved into the thesis for an entirely new operating model, which we now call Pipeline-in-a-Person,” wrote Cody Tranbarger, Mithril’s former chief executive and lone employee, on LinkedIn. (Tranbarger, who works for Anthropic since Mithril was absorbed into it, declined to speak to Nature, as did Anthropic.)
doi: https://doi.org/10.1038/d41586-026-03640-9
Related Articles
-
Will self-driving ‘robot labs’ replace biologists? Paper sparks debate
-
AI ‘scientists’ joined these research teams: here’s what happened
-
Virtual lab powered by ‘AI scientists’ super-charges biomedical research
Subjects
Latest on:
-
Biotech innovations are an opportunity to limit climate change
Editorial 11 NOV 26
-
Engineered bacteria are weaning farms away from synthetic fertilizers
News 11 NOV 26
-
Cholera bacterium’s good deed: inspiring a glue with rare properties
Research Highlight 06 NOV 26
来源:Nature 综合主刊 · nature.com


How I use AI to turn failed drugs into new medicines